

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

CLARIFICATION ANNOUNCEMENT IN RELATION TO PROPOSED ADOPTION OF SHARE OPTION SCHEME

Reference is made to the announcement of Beijing Biostar Pharmaceuticals Co., Ltd. (the “**Company**”) dated 7 May 2026 (the “**Announcement**”) in relation to, among others, the proposed adoption of the Share Option Scheme. Unless the context otherwise requires, capitalised terms used herein shall have the same meaning as defined in the Announcement.

The Board of Directors (the “**Board**”) of the Company wishes to clarify that a clerical error was inadvertently made in section 10(b) “Employee Sublimit” on page 5 of the Announcement. The Board would like to clarify that the relevant paragraph should be read as follows (with the correction underlined for easy reference):

Original Text

“(b) **Employee Sublimit:** The total number of shares involved in awards granted or to be granted to a qualified participant (including exercised, cancelled, and unexercised awards) shall not exceed 10% of the issued share capital of the company.”

Clarified Text

(b) **Employee Sublimit:** The total number of shares involved in awards granted or to be granted to a qualified participant (including exercised, cancelled, and unexercised awards) shall not exceed 1% of the issued share capital of the company.

Save for the above clarification, all other information and contents contained in the Announcement remain unchanged. The Board apologises for any inconvenience this typographical error may have caused.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 26 May 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.